

Arix Bioscience PLC

08:15 16 Apr 2019

Arix Bioscience portfolio company Autolus Therapeutics raises US\$109m

Autolus Therapeutics PLC (NASDAQ:AUTL), a portfolio company of biotech investor Arix Bioscience PLC (LON:ARIX), has raised more than expected from its recent public offering.

Autolus, which is developing next-gen cancer immunotherapies, had originally set out to raise US\$100.8m through the issue of 4.2m American Depositary Shares (ADS) at US\$24.00 apiece.

READ: Arix to invest another US\$5m in Autolus
But it ended up issuing 4.83m ADS at the same price to raise US\$109.0m.

As part of the offering, Arix agreed to invest US\$5m, keeping its stake in Autolus at 7.5%, which is currently valued at US\$94m (£72m).

Speaking last week, Arix chief executive Joe Anderson said: "Our investment in Autolus demonstrates our strategy to build world-leading biotech companies through the provision of flexible, long term capital.

"We believe Autolus is at the forefront of a revolution in cancer treatment and that its innovative approach to T-cell programming has the potential to offer life-changing therapies for patients."

Price: 133.5p

Market Cap: £180.96M

1 Year Share Price Graph



Share Information

Code: ARIX

Listing: LSE

52 week High Low
182.00p 130.00p

Sector: Health Care, Equipment & Services [T3]

Website: arixbioscience.com

Company Synopsis:

Arix Bioscience is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks needed to help accelerate their ideas into important new treatments for patients.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.